OXAPROZIN | N217927 | SOLUBIOMIX LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Senores Pharmaceuticals, Inc. FDA-2026-P-3665 Senores Pharmaceuticals, Inc. filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Oxaprozin Capsules, 600 mg suitable for submission in an Abbreviated New Drug Application, with the reference listed drug being COXANTO | Suitability | 2026-04-03 | Open | Senores Pharmaceuticals |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.